drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (TCR-T)
drug_description
Autologous gene-engineered T cells expressing an HLA-A*02:01–restricted TCR targeting the HPV16 E7 peptide; adoptive cellular gene therapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Adoptive Transfer
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an HLA-A*02:01–restricted T-cell receptor specific for the HPV16 E7 peptide. After infusion, these TCR-T cells recognize E7 peptide presented on tumor MHC class I, become activated, expand, and kill antigen-positive cancer cells via cytotoxic effector mechanisms (perforin/granzyme and cytokine-mediated responses).
drug_name
E7 TCR-T cells
nct_id_drug_ref
NCT05686226